Neonatal screening for congenital adrenal hyperplasia: considerations regarding the transient rise of the 17-hydroxyprogesterone - doi:10.5020/18061230.2006.p203

Detalhes bibliográficos
Autor(a) principal: Alves, Crésio
Data de Publicação: 2012
Outros Autores: Balesteri Júnior, Valdi, Toralles, Maria Betânia Pereira
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Brasileira em Promoção da Saúde
Texto Completo: https://ojs.unifor.br/RBPS/article/view/983
Resumo: The transient rise in 17-hidroxiprogesterone (17-OHP) diagnosed by neonatal screening test (NST) may lead to the incorrect diagnosis of congenital adrenal hyperplasia. To investigate this condition, a retrospective study was conducted on medical registers of patients with this disorder and attended at a reference unit, in the last five years. Ten children (6 girls) were evaluated. Five were full-term newborns (FTN), with gestational age (GA) of 39.2±0.5 weeks and birth weight (BW) 3.2±0.3 kg; and five were preterm (PTN) with GA of 32.4±2.5 weeks and BW 1.8±0.6 kg. The 17-OHP in the NST was measured between 3-25 days (9.2±5.8 days), presenting the following results: FTN 20.1±5.9 ng/mL (< 10 ng/mL) and PTN 23.6±9.0 (< 15 ng/mL). During the follow-up, the 17-OHP returned to normal values in 7.5±2.4 months. There were no changes in serum glucose and electrolytes. None of the patients had genital ambiguity, salt-losing crisis, and family history of adrenal disorder or needed corticotherapy. It follows that NST using only two reference values for 17-OHP (FTN and PTN) may yield false-positives results. Children with rise of the 17-OHP in the NST and normal physical examination may be followed as outpatients with special attention to dehydration; and having monthly laboratory determination of 17-OHP and electrolytes. The progressive drop of 17-OHP suggests that have had a transient rise of this hormone. In these cases, it’s advisable to not initiate corticotherapy and to monitor the 17-OHP return to normality. The authors recommend an update of the 17-OHP cut-off values in the NST based on gestational age.
id UFOR-2_09deff099c836c75f35474d51c52fda7
oai_identifier_str oai:ojs.ojs.unifor.br:article/983
network_acronym_str UFOR-2
network_name_str Revista Brasileira em Promoção da Saúde
repository_id_str
spelling Neonatal screening for congenital adrenal hyperplasia: considerations regarding the transient rise of the 17-hydroxyprogesterone - doi:10.5020/18061230.2006.p203Triagem neonatal para hiperplasia adrenal congênita: considerações sobre a elevação transitória da 17-hidroxiprogesterona - doi:10.5020/18061230.2006.p20317-hidroxiprogesteronaTriagem neonatalTriagem do recém-nascido.The transient rise in 17-hidroxiprogesterone (17-OHP) diagnosed by neonatal screening test (NST) may lead to the incorrect diagnosis of congenital adrenal hyperplasia. To investigate this condition, a retrospective study was conducted on medical registers of patients with this disorder and attended at a reference unit, in the last five years. Ten children (6 girls) were evaluated. Five were full-term newborns (FTN), with gestational age (GA) of 39.2±0.5 weeks and birth weight (BW) 3.2±0.3 kg; and five were preterm (PTN) with GA of 32.4±2.5 weeks and BW 1.8±0.6 kg. The 17-OHP in the NST was measured between 3-25 days (9.2±5.8 days), presenting the following results: FTN 20.1±5.9 ng/mL (< 10 ng/mL) and PTN 23.6±9.0 (< 15 ng/mL). During the follow-up, the 17-OHP returned to normal values in 7.5±2.4 months. There were no changes in serum glucose and electrolytes. None of the patients had genital ambiguity, salt-losing crisis, and family history of adrenal disorder or needed corticotherapy. It follows that NST using only two reference values for 17-OHP (FTN and PTN) may yield false-positives results. Children with rise of the 17-OHP in the NST and normal physical examination may be followed as outpatients with special attention to dehydration; and having monthly laboratory determination of 17-OHP and electrolytes. The progressive drop of 17-OHP suggests that have had a transient rise of this hormone. In these cases, it’s advisable to not initiate corticotherapy and to monitor the 17-OHP return to normality. The authors recommend an update of the 17-OHP cut-off values in the NST based on gestational age.A elevação transitória da 17-hidroxiprogesterona (17-OHP) diagnosticada pelo teste de rastreamento neonatal (TP) pode levar ao diagnóstico incorreto de hiperplasia adrenal congênita. Para investigar esta condição, realizou-se estudo retrospectivo dos prontuários de pacientes com este distúrbio, atendidos num centro de referência, nos últimos cinco anos. Foram avaliadas 10 crianças (6 meninas), destas cinco eram recém-nascidas a termo (RNT), com idade gestacional (IG) 39,2±0,5 semanas e peso ao nascer (PN) de 3,2±0,3 Kg; e 5 eram prematuras (RNPT) com IG 32,4±2,5 semanas e PN 1,8±0,6 Kg. A 17-OHP no TP foi dosada entre 3-25 dias (9,2±5,8 dias), apresentando os seguintes resultados: RNT 20,1±5,9 ng/mL (VR: < 10 ng/mL) e RNPT 23,6±9,0 (VR < 15 ng/mL). Durante o acompanhamento, a 17-OHP retornou à normalidade entre 7,5±2,4 meses. Não foram encontradas alterações nos eletrólitos ou glicemia. Nenhuma criança apresentou ambigüidade genital, crise de perda de sal, história familiar de doença adrenal ou necessitou de corticoterapia. Conclui-se que testes de triagem neonatal que usam apenas dois valores de referência (RNT e RNPT) podem levar a resultados falso-positivos. Crianças com elevação da 17-OHP no TP e exame físico normal podem ser acompanhadas clinicamente com atenção para desidratação, e laboratorialmente com dosagens mensais da 17-OHP e eletrólitos. A queda progressiva dos valores da 17-OHP sugere ter havido elevação transitória desse hormônio. Nestes casos, não iniciar corticoterapia e monitorar o retorno à normalidade. Recomenda-se que o ponto de corte da 17-OHP no TP seja atualizado com definição de valores de referências baseados na idade gestacional.Universidade de Fortaleza2012-01-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion"Peer-reviewed Article""Avaliado pelos pares""Avaliado pelos pares"application/pdfhttps://ojs.unifor.br/RBPS/article/view/98310.5020/983Brazilian Journal in Health Promotion; Vol. 19 No. 4 (2006); 203-208Revista Brasileña en Promoción de la Salud; Vol. 19 Núm. 4 (2006); 203-208Revista Brasileira em Promoção da Saúde; v. 19 n. 4 (2006); 203-2081806-1230reponame:Revista Brasileira em Promoção da Saúdeinstname:Universidade de Fortaleza (Unifor)instacron:UFORporhttps://ojs.unifor.br/RBPS/article/view/983/2145Alves, CrésioBalesteri Júnior, ValdiToralles, Maria Betânia Pereirainfo:eu-repo/semantics/openAccess2012-01-10T12:18:22Zoai:ojs.ojs.unifor.br:article/983Revistahttps://periodicos.unifor.br/RBPS/oai1806-12301806-1222opendoar:2012-01-10T12:18:22Revista Brasileira em Promoção da Saúde - Universidade de Fortaleza (Unifor)false
dc.title.none.fl_str_mv Neonatal screening for congenital adrenal hyperplasia: considerations regarding the transient rise of the 17-hydroxyprogesterone - doi:10.5020/18061230.2006.p203
Triagem neonatal para hiperplasia adrenal congênita: considerações sobre a elevação transitória da 17-hidroxiprogesterona - doi:10.5020/18061230.2006.p203
title Neonatal screening for congenital adrenal hyperplasia: considerations regarding the transient rise of the 17-hydroxyprogesterone - doi:10.5020/18061230.2006.p203
spellingShingle Neonatal screening for congenital adrenal hyperplasia: considerations regarding the transient rise of the 17-hydroxyprogesterone - doi:10.5020/18061230.2006.p203
Alves, Crésio
17-hidroxiprogesterona
Triagem neonatal
Triagem do recém-nascido.
title_short Neonatal screening for congenital adrenal hyperplasia: considerations regarding the transient rise of the 17-hydroxyprogesterone - doi:10.5020/18061230.2006.p203
title_full Neonatal screening for congenital adrenal hyperplasia: considerations regarding the transient rise of the 17-hydroxyprogesterone - doi:10.5020/18061230.2006.p203
title_fullStr Neonatal screening for congenital adrenal hyperplasia: considerations regarding the transient rise of the 17-hydroxyprogesterone - doi:10.5020/18061230.2006.p203
title_full_unstemmed Neonatal screening for congenital adrenal hyperplasia: considerations regarding the transient rise of the 17-hydroxyprogesterone - doi:10.5020/18061230.2006.p203
title_sort Neonatal screening for congenital adrenal hyperplasia: considerations regarding the transient rise of the 17-hydroxyprogesterone - doi:10.5020/18061230.2006.p203
author Alves, Crésio
author_facet Alves, Crésio
Balesteri Júnior, Valdi
Toralles, Maria Betânia Pereira
author_role author
author2 Balesteri Júnior, Valdi
Toralles, Maria Betânia Pereira
author2_role author
author
dc.contributor.author.fl_str_mv Alves, Crésio
Balesteri Júnior, Valdi
Toralles, Maria Betânia Pereira
dc.subject.por.fl_str_mv 17-hidroxiprogesterona
Triagem neonatal
Triagem do recém-nascido.
topic 17-hidroxiprogesterona
Triagem neonatal
Triagem do recém-nascido.
description The transient rise in 17-hidroxiprogesterone (17-OHP) diagnosed by neonatal screening test (NST) may lead to the incorrect diagnosis of congenital adrenal hyperplasia. To investigate this condition, a retrospective study was conducted on medical registers of patients with this disorder and attended at a reference unit, in the last five years. Ten children (6 girls) were evaluated. Five were full-term newborns (FTN), with gestational age (GA) of 39.2±0.5 weeks and birth weight (BW) 3.2±0.3 kg; and five were preterm (PTN) with GA of 32.4±2.5 weeks and BW 1.8±0.6 kg. The 17-OHP in the NST was measured between 3-25 days (9.2±5.8 days), presenting the following results: FTN 20.1±5.9 ng/mL (< 10 ng/mL) and PTN 23.6±9.0 (< 15 ng/mL). During the follow-up, the 17-OHP returned to normal values in 7.5±2.4 months. There were no changes in serum glucose and electrolytes. None of the patients had genital ambiguity, salt-losing crisis, and family history of adrenal disorder or needed corticotherapy. It follows that NST using only two reference values for 17-OHP (FTN and PTN) may yield false-positives results. Children with rise of the 17-OHP in the NST and normal physical examination may be followed as outpatients with special attention to dehydration; and having monthly laboratory determination of 17-OHP and electrolytes. The progressive drop of 17-OHP suggests that have had a transient rise of this hormone. In these cases, it’s advisable to not initiate corticotherapy and to monitor the 17-OHP return to normality. The authors recommend an update of the 17-OHP cut-off values in the NST based on gestational age.
publishDate 2012
dc.date.none.fl_str_mv 2012-01-04
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
"Peer-reviewed Article"
"Avaliado pelos pares"
"Avaliado pelos pares"
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://ojs.unifor.br/RBPS/article/view/983
10.5020/983
url https://ojs.unifor.br/RBPS/article/view/983
identifier_str_mv 10.5020/983
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://ojs.unifor.br/RBPS/article/view/983/2145
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de Fortaleza
publisher.none.fl_str_mv Universidade de Fortaleza
dc.source.none.fl_str_mv Brazilian Journal in Health Promotion; Vol. 19 No. 4 (2006); 203-208
Revista Brasileña en Promoción de la Salud; Vol. 19 Núm. 4 (2006); 203-208
Revista Brasileira em Promoção da Saúde; v. 19 n. 4 (2006); 203-208
1806-1230
reponame:Revista Brasileira em Promoção da Saúde
instname:Universidade de Fortaleza (Unifor)
instacron:UFOR
instname_str Universidade de Fortaleza (Unifor)
instacron_str UFOR
institution UFOR
reponame_str Revista Brasileira em Promoção da Saúde
collection Revista Brasileira em Promoção da Saúde
repository.name.fl_str_mv Revista Brasileira em Promoção da Saúde - Universidade de Fortaleza (Unifor)
repository.mail.fl_str_mv
_version_ 1808844174271709184